Current investment in antimicrobial R&D is insufficient to address growing resistance. US policymakers agree that innovative reimbursement models, if properly aligned with public health goals, could both boost innovation and enable appropriate patient access to critically-needed antibiotics. To date, none has been implemented. As part of a suite of incentives including push and pull incentives, reimbursement reform could help create a more sustainable antibiotic market.
This panel will describe potential reimbursement reform and innovative payment models in the US. Attendees engaged in infectious disease R&D and reimbursement policy reform will learn:
• What reimbursement reform and innovative payment models could look like in the US, and what’s possible in the short term;
• How to measure the true societal value of novel antibiotics;
• How new payment and reimbursement models support appropriate use of novel antibiotics and what changes to stewardship programs are needed to enable them
Ability Level: Advanced
Session ID: 503665